Accelerates Trulieve’s expansion as a Multi-State Operator entering fifth state and reaching 71 stores nationally

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the closing of the acquisition of all of the issued and outstanding equity interests of cultivator and producer PurePenn LLC and Pioneer Leasing & Consulting LLC (collectively, “PurePenn”) and dispensary operator Keystone Relief Centers LLC, doing business as Solevo Wellness (“Solevo”) previously announced September 16, 2020 .


As previously announced, total upfront consideration for both the Pure Penn and Solevo transactions was $66 million , on a combined basis, which Trulieve satisfied through the payment of $29 million in cash and by the issuance of 1,780,062 subordinate voting shares of the Company (the “Trulieve Shares”).  Each transaction provides for a potential earn-out payment in Trulieve Shares based on the ‎achievement of certain agreed EBITDA milestones.‎ The Trulieve Shares issued on closing of the PurePenn and Solevo transactions are subject to various hold periods of ‎up to 18 months‎.

Trulieve CEO Kim Rivers stated, “We are pleased to complete these transactions, which strengthens our presence in the northeast and provides us with a new operating state. PurePenn and Solevo are proven and reputable operators and we’ve appreciated the community support we’ve received from the McKeesport community, Mayor Michael Cherepko , Senator James Brewster , Representative Austin Davis and County Executive Rich Fitzgerald during this entire process. We look forward to serving patients in the Pennsylvania market, one of the most attractive medical marijuana markets in the United States .”

PurePenn is a premier cultivation and production company, producing medical marijuana products. It offers a range of products such as concentrates, flower, oil, capsules and tinctures, and its portfolio includes some of the highest THC potencies in the Pennsylvania program, with 750mg THC per 30mL bottle tincture and the original THCA sand with potencies in excess of 96%. PurePenn currently operates a 35,000 square foot cultivation and processing facility in McKeesport, PA , which is undergoing expansion to 90,000 square feet expected to be operational by Q1 2021. The PurePenn facility also provides room for future expansion as it grows its operations in Pennsylvania .

“We look forward to joining the Trulieve team,” said Gabe Perlow , CEO of PurePenn. “We are very proud of the cultivation and processing business we established and believe Trulieve places PurePenn in a great position to scale up our operations to meet the wholesale demand in the Commonwealth of Pennsylvania .”

Solevo owns and operates three dispensaries, located in premier Pittsburgh -area locations, including the first dispensary to open in Allegheny County . Solevo provides medical marijuana relief solutions for Pennsylvanians certified with serious medical conditions.

“Solevo and Trulieve share the same values, particularly as it relates to how we both treat patients,” said Dr. Robert Capretto , Chairman of the Board of Solevo. “As we enter this next phase of growth, we are excited to continue meeting patient-demand and look forward to bringing Trulieve values to the Pennsylvania market.”

For more information on the acquisitions, please see the news release previously issued by Trulieve on September 16, 2020 , which is available on Trulieve’s website as well as SEDAR at www.sedar.com .

About Trulieve

Trulieve is a vertically integrated “seed-to-sale” company outside of Pennsylvania and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts , and Connecticut . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.  Learn more at: www.trulieve.com/

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but ‎are not limited to, information and statements regarding or inferring the future business, ‎operations, financial performance, prospects, and other plans, intentions, expectations, estimates, ‎and beliefs of the Company and statements with regard to the issuance of additional Trulieve Shares in satisfaction of earn-out payments and the expansion of the Company’s operations. Words such as “expects”, ‎‎”continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify ‎forward-looking statements. These forward-looking statements are based on the Company’s ‎current projections and expectations about future events and financial trends that management ‎believes might affect its financial condition, results of operations, business strategy and financial ‎needs, and on certain assumptions and analysis made by the Company in light of the experience ‎and perception of historical trends, current conditions and expected future developments and ‎other factors management believes are appropriate. Forward-looking information and statements ‎involve and are subject to assumptions and known and unknown risks, uncertainties, and other ‎factors which may cause actual events, results, performance, or achievements of the Company ‎to be materially different from future events, results, performance, and achievements expressed ‎or implied by forward-looking information and statements herein. Although the Company ‎believes that any forward-looking information and statements herein are reasonable, in light of ‎the use of assumptions and the significant risks and uncertainties inherent in such information ‎and statements, there can be no assurance that any such forward-looking information and ‎statements will prove to be accurate, and accordingly readers are advised to rely on their own ‎evaluation of such risks and uncertainties and should not place undue reliance upon such ‎forward-looking information and statements. Any forward-looking information and statements ‎herein are made as of the date hereof, and except as required by applicable laws, the Company ‎assumes no obligation and disclaims any intention to update or revise any forward-looking ‎information and statements herein or to update the reasons that actual events or results could or ‎do differ from those projected in any forward looking information and statements herein, whether ‎as a result of new information, future events or results, or otherwise, except as required by ‎applicable laws.‎

The Canadian Securities Exchange has not reviewed, approved, or disapproved the ‎content of this news release.‎

SOURCE Trulieve Cannabis Corp.

Cision View original content: http://www.newswire.ca/en/releases/archive/November2020/12/c5607.html

News Provided by Canada Newswire via QuoteMedia

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less